About this episode
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.
We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
Get every episode summarized
Each time Two Onc Docs publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
